A just-reported Chinese study compares the clinical outcomes of COVID-19 patients treated with hydroxychloroquine with those of patients receiving standard of care. The results, alas, are disappointing.I summarized that study in my roundup yesterday of COVID-19 therapeutic research, pointing out that this randomized controlled trial of 150 patients "found no difference in the rate of viral load reduction or symptom alleviation between the group treated with hydroxychloroquine and the one that had not been." Now the University of Vermont pulmonologist Josh Farkas has published his own analysis of the results, delving more deeply into the data.The patients in both arms...